Skip to main content

Table 1 Demographic and clinical characteristics of the intent-to-treat population at screening

From: Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial

Characteristic

Pyronaridine-artesunate

Artemether-lumefantrine

n = 355

n = 180

Male, n (%)

177 (49.9)

84 (46.7)

Mean age, years (SD) [range]

4.9 (2.5) [0.3–11]

5.3 (2.5) [0.3–12]

  <1 year, n (%)

12 (3.4)

3 (1.7)

  1– < 5 years, n (%)

148 (41.7)

69 (38.3)

  5–12 years, n (%)

195 (54.9)

108 (60.0)

Ethnicity, n (%)

  Black

342 (96.3)

172 (95.6)

  Asian/Oriental

13 (3.7)

8 (4.4)

Mean weight, kg (SD) [range]

16.3 (4.1) [6.0–24.8]

17.1 (4.4) [7.2–24.9]

Mean body mass index, kg/m2 (SD) [range]

15.0 (2.2) [6.0–24.5]

15.1 (2.3) [10.7–25.0]

Geometric mean asexual parasites per μL

18565.9

18798.3

(95% CI)

(16005.9, 21535.4)

(15243.1, 23182.7)

Patients with gametocytes, n (%)

43 (12.1)

25 (13.9)

Temperature, °C

38.0 (1.1) [35.9–41.5]

37.8 (1.1) [35.4–41.0]

Fever at screening, n (%)

230 (65.0)

107 (59.4)

No previous malaria infection, n (%)

130 (36.7)

59 (32.8)

Malaria in last 12 months, n (%)a

  None

143 (41.1)

65 (36.7)

  1

65 (18.7)

34 (19.2)

  2

56 (16.1)

35 (19.8)

  >2

84 (24.1)

43 (24.3)

  1. a Malaria in last 12 months; status was unknown for 10 patients.